-----BEGIN PRIVACY-ENHANCED MESSAGE----- Proc-Type: 2001,MIC-CLEAR Originator-Name: webmaster@www.sec.gov Originator-Key-Asymmetric: MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB MIC-Info: RSA-MD5,RSA, McxqSe1RTQxyGw0Q9OIU3XdAzZNk9gpq0ASMUl9VYdzHAYYr+rn9g0m7tNjSdcJh NQKZPEfaPxDjfAVJbT8PBQ== 0000739944-97-000017.txt : 19970918 0000739944-97-000017.hdr.sgml : 19970918 ACCESSION NUMBER: 0000739944-97-000017 CONFORMED SUBMISSION TYPE: 10-K/A PUBLIC DOCUMENT COUNT: 3 CONFORMED PERIOD OF REPORT: 19961231 FILED AS OF DATE: 19970917 SROS: AMEX FILER: COMPANY DATA: COMPANY CONFORMED NAME: MEDTOX SCIENTIFIC INC CENTRAL INDEX KEY: 0000739944 STANDARD INDUSTRIAL CLASSIFICATION: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES [2835] IRS NUMBER: 953863205 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-K/A SEC ACT: SEC FILE NUMBER: 001-11394 FILM NUMBER: 97681544 BUSINESS ADDRESS: STREET 1: 1238 ANTHONY RD CITY: BURLINGTON STATE: NC ZIP: 27215 BUSINESS PHONE: 9102266311 MAIL ADDRESS: STREET 1: 1238 ANOTHNY ROAD CITY: BURLINGTON STATE: NC ZIP: 27215 FORMER COMPANY: FORMER CONFORMED NAME: EDITEK INC DATE OF NAME CHANGE: 19940902 FORMER COMPANY: FORMER CONFORMED NAME: ENVIRONMENTAL DIAGNOSTICS INC DATE OF NAME CHANGE: 19920703 10-K/A 1 1996 10-K/A-2 SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K/A-2 [X] ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [FEE REQUIRED] For the fiscal year ended December 31, 1996 [ ] TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 [NO FEE REQUIRED] Commission file number 1-11394 EDITEK, INC. (Exact name of Registrant as specified in its charter) Delaware 95-3863205 (State or other jurisdiction of (I.R.S. Employer incorporation or organization) Identification No.) 1238 Anthony Road, Burlington, North Carolina 27215 (Address of principal executive offices) (Zip Code) Registrant's telephone number, including area code: (910) 226-6311 Securities registered pursuant to Section 12(b) of the Act: Common Stock, par value $.15 per share (Title of Class) Securities registered pursuant to Section 12(g) of the Act: None Indicate by check mark whether the Registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the Registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes X No __ Indicate by check mark if disclosure of delinquent filers pursuant to Item 405 of Regulation S-K (229.405 of this chapter) is not contained herein, and will not be contained, to the best of registrant's knowledge, in definitive proxy or information statements incorporated by reference in Part III of this Form 10-K or any amendment to this Form 10-K. [X] The aggregate market value of Common Stock of the Registrant, $.15 par value ("Common Stock"), held by non-affiliates of the Registrant is approximately $15,866,288, as of March 14, 1997, based upon a price of $.38 which price is equal to the closing price for the Common Stock on the American Stock Exchange. The number of shares of Common Stock outstanding as of March 14, 1997, was 48,692,775. This document contains 58 pages and the Exhibit Index appears at page 31 hereof. ITEM 1. BUSINESS. 1. General. EDITEK, Inc., a Delaware corporation, was organized in September, 1986 to succeed the operations of a predecessor California corporation. EDITEK, Inc. and its subsidiaries are referred to herein as "the Company". The Company currently operates a toxicology laboratory which provides forensic toxicology, clinical toxicology, and heavy metals analyses. The Company also develops, manufactures and markets on-site diagnostic and screening tests which are used to detect substances in humans, foodstuffs, animals, feed and the environment. The Company entered the laboratory business on February 11, 1994 when it completed the acquisition of Princeton Diagnostic Laboratories of America, Inc. ("PDLA"). On January 30, 1996, the Company acquired the assets and certain liabilities of another laboratory, MEDTOX Laboratories, Inc. ("MEDTOX"). MEDTOX is now a wholly owned subsidiary. For the fiscal year ended December 31, 1996, sales from laboratory services accounted for 88% of the Company's revenues. Revenue from the sale of the Company's on-site diagnostic and screening tests and other products, including contract manufacturing services, accounted for 11% of the total revenues of the Company for the year ended December 31, 1996. The balance of the Company's revenues are from work performed for the U.S. Department of Defense including product sales as well as royalties, fees and other income. This represented approximately 1% of the revenues of the Company for the year ended December 31, 1996. 2. Principal Services, Products, and Markets. General. The Company's principal sources of revenues come from the sale of laboratory testing services in forensic toxicology, clinical toxicology, and heavy metal analyses as well as from manufactured products including a variety of on-site screening products. A. Drug Abuse Laboratory Testing Services. The primary source of revenues of the Company is the provision of laboratory testing services for the identification of drugs of abuse. These tests are conducted using methodologies such as various immunoassays, gas liquid chromatography, high pressure liquid chromatography and gas chromatography/mass spectrometry. The Company has pioneered security and chain of custody procedures, including sample bar coding as well as stereospecific confirmation methods, to help maintain the integrity of the specimens and the confidentiality of the test results. The Company's customers for abused substance testing include public and private corporations. Among this customer base are Fortune 500 companies. In addition to public and private corporations, abused substance testing is also conducted on behalf of service firms such as financial institutions, drug treatment counseling centers and hospitals. B. Clinical Toxicology. The Company has a fully certified clinical toxicology reference laboratory specializing in esoteric therapeutic drug monitoring and emergency toxicology. The tests performed in the clinical laboratory are conducted using methodologies such as radio immunoassay, gas liquid chromatography, high performance liquid chromatography and gas chromatography/mass spectrometry. The Company performs the analyses on many classes of drugs including: analgesic, antianxiety, anticholinergic, antocoagulant, anticonvulsant, antidepressant, antidiabetic, antiemetic, antihistamine, antiinflammatory, antimicrobial, antipsychotic, bronchodilotar, cardiovascular, stimulant, decongestant, immunosuppressant, local anesthetic, muscle relaxant, narcotic analgesic, and sedative medications. The Company's clients for this market consist of hospitals, clinics and other laboratories. C. Heavy metal, trace element, and solvent analyses. The Company also operates a laboratory in which blood and urine are tested for heavy metals, trace elements, and solvents. The tests are performed using the methodologies such as Flame and Flameless Atomic Absorption and the Inductively Coupled Plasma-Mass Spectrometry. The Company's clients for this market are occupational health clinics and companies which need to test patients or employees monitored for excess exposure to hazardous materials. D. Products. The Company's test products, which were adapted from assay technologies previously developed in the 1970's for human medical diagnostics, are easy to use, inexpensive, on-site tests. The tests are capable of rapidly detecting the presence of a number of substances in human urine or blood samples, foodstuffs, animals, feed and the environment without the necessity of instruments or technical personnel. The Company's diagnostic tests and the disposable devices used in connection therewith are marketed under the names EZ-SCREEN(R), QUIK-CARD(R), VERDICT(R), PROFILE(R), RECON(R), and EZ-QUANT(R), which are registered trademarks of the Company. A QUIK-CARD together with the necessary reagents, comprise an EZ-SCREEN test. EZ-SCREEN and VERDICT tests are utilized in agricultural diagnostics (which includes mycotoxin detection, drug residue surveillance, feed analysis, and regulatory compliance) and clinical diagnostics (which includes drugs of abuse testing). VERDICT and RECON are "self-performing", one-step tests marketed, respectively, to the drugs of abuse and Department of Defense testing markets. The EZ-QUANT tests are microtiter, ELISA-based, quantitative assays utilized in agricultural diagnostics. The EZ-SCREEN tests are used in clinical diagnostics to detect the presence of certain drugs of abuse in humans. The Company now has received clearance from the Food and Drug Administration ("FDA") for EZ-SCREEN tests for six of the most commonly abused substances: cannabinoids, cocaine, opiates, barbiturates, amphetamines, and PCP. The Company markets this product line, both domestically and internationally, to law enforcement agencies, industrial companies for pre-employment screening, physicians' offices, hospitals, clinics and drug abuse counseling and treatment centers. VERDICT tests are used to detect the presence of certain drugs of abuse in humans. The Company is now marketing the one-step VERDICT tests for cocaine, THC, opiates, barbiturates and PCP, all of which have received 510(k) premarket clearance from the FDA. The Company distributes on-site tests for the detection of alcohol with the EZ-SCREEN Breath Alcohol Test. The test consists of a small tube containing chemically treated crystals that change color in the presence of alcohol. The Company purchases these products through a distribution agreement. The EZ-SCREEN and EZ-QUANT tests are used in agricultural diagnostics to detect, among other things, mycotoxins, which are hazardous substances produced by fungal growth. Mycotoxins frequently contaminate corn, wheat, rye, barley, peanuts, tree nuts, cottonseed, milk, rice, and livestock feeds. The EZ-SCREEN agridiagnostic tests are marketed to regulatory authorities and producers of foodstuffs and feeds. 3. Marketing and Sales. The Company believes that the combined operations of the laboratory operations and the on-site test kits manufactured by the Company have created synergy in the marketing of comprehensive, on-site and laboratory testing programs to a common customer base. The Company is in a position to offer a full line of products and services for the substance abuse testing marketplace, including (1) on-site tests for the detection of substance of abuse drugs (EZ-SCREEN and VERDICT); (2) on-site qualitative and quantitative determination of alcohol intoxication (both disposable and electronic instrument detection devices); (3) SAMHSA certified laboratory testing (screening and confirmation); (4) accessory items (gloves, specimen containers, permanent recording temperature strips); (5) consultation; and (6) coordination of collection site services. The Company currently markets these products and services through its dedicated sales force, through independent third party administrators and through occupational health clinics. Through most of the year ended December 31, 1996, the Company sold its agricultural diagnostic products through its wholly owned subsidiary, DIAGNOSTIX, Inc., which consisted primarily of the former operations of Bioman Products which the Company acquired in June, 1995. In order to reduce its overall operating costs and focus its attention on the laboratory sales effort, the Company, in September of 1996, sold certain assets and the operations of DIAGNOSTIX, Inc., including the trade name DIAGNOSTIX, to a company headed by certain former employees of DIAGNOSTIX, Inc. The Company continues to sell its agridiagnostic products direct or through the use of certain distributors. Major Customers. The Company had no single customer whose sales amounted to more than 10% of its total revenues during the year ended December 31, 1996. One customer's sales amounted to approximately 6% of the Company's laboratory revenues while sales to the United States government and its agencies, primarily the United States Department of Agriculture ("USDA"), amounted to approximately 9% of the Company's revenues from product sales. Sales to foreign customers, primarily distributors, amounted to approximately 10% of the Company's revenues from product sales. No one foreign customer represented more than 5% of the Company's revenue from product sales. 4. New Products. During 1996 the primary research and development efforts of the Company focused on the development of tests to extend the product offerings in each of the immunoassay product lines produced by the Company. These product lines consist of the VERDICT/RECON "self-performing" immunochromatographic assays, the EZ-SCREEN membrane-based enzyme immunoassays, and the EZ-QUANT microtiter immunoassays. VERDICT Tests for Drugs of Abuse - During 1996 research and development efforts were directed to continued support and refinement of the currently marketed VERDICT one-step tests for the detection of cocaine, THC (marijuana), and opiate metabolites and to the development of additional VERDICT tests for the detection of phencyclidine (PCP), amphetamines and barbiturates. The Company received 510(k) premarket clearance for the VERDICT THC (marijuana), barbiturates, and phencyclidine (PCP) tests from the U.S. Food and Drug Administration (FDA) in 1996. In 1997, efforts will be directed to the development of a VERDICT amphetamine test kit as well as designing and developing a test device which would permit simultaneous testing of a sample for five different drugs of abuse on a one-step format. RECON Tests for Agents of Biological Origin - In 1991 the Company successfully completed a "proof of principle" study under contract with the U.S. Department of Defense (DOD) to develop rapid, on-site tests for the detection of certain biological materials. From September 1991 to September 30, 1996, the Company had a contract to develop tests on the EZ-SCREEN format as well as on a one-step format (RECON test kits). The Company successfully developed a total of 14 tests during the contract. EZ-SCREEN Tests for Drugs of Abuse - In 1996, the Company completed the development of, and received FDA 510(k) premarket clearance for the EZ-SCREEN PROFILE drugs of abuse test. This product permits simultaneous testing of a single urine sample for THC, cocaine, opiates, amphetamines and PCP. The Company is also working on the development of a test for LSD (lysergic acid diethylamide) and testing of meconium specimens on the EZ-SCREEN format. EZ-QUANT Tests for Mycotoxins and Antibiotic Residues - In 1996, the Company completed development of the EZ-QUANT Chloramphenicol test. No additional test development is planned for 1997. Biosensors - In March, 1995 the Company entered into a Research Collaboration Agreement with Battelle Memorial Institute ("Battelle") to explore the commercial feasibility of utilizing the Company's immunoassay reagents with a novel, state-of-the-art biosensor instrument developed by Battelle under contract with the Department of Defense. During 1996, the project was completed and a final report has been prepared by Battelle. The report shows that the biosensor instrument coupled with the Company's immunoassay reagents generated results that looked promising in that the instrument was able to detect the target toxin at levels which would be associated with that toxin's contamination of grains and food products. At this time, the Company does not intend to pursue any further development of this project. Laboratory Services - The research and development department of MEDTOX develops new assays for new drug entities, develops new assays for existing metabolites of drugs and other toxins, and improving existing assays with the goals of improving the assays' robustness, sensitivity, accuracy, precision, specificity, and cost. Historical R&D activities at MEDTOX have used the primary technologies of liquid chromatography (LC), gas chromatography (GC), gas chromatography with mass spectrometry (GC/MS), and atomic absorption. During 1996, MEDTOX switched most of the activities in the atomic absorption area, for the measurement of metals and other elements, to the innovative technology of inductively coupled plasma mass spectrometry (ICP/MS). ICP/MS was used in 1996 both for the development of assays for elements that had not been previously analyzed by MEDTOX, and for the development of improved and less expensive assays for elements previously measured at MEDTOX by atomic absorption. In 1997, MEDTOX will attempt to attain improved results using the new technology of tandem mass spectrometry coupled with both gas chromatography and liquid chromatography (GC/MS/MS and LC/MS/MS). These new technologies should allow MEDTOX to compete more successfully in our markets due to decreased assay development time, reduced cost, enhanced sensitivity, and enhanced specificity. The Company believes that these technologies will improve our laboratory services in clinical toxicology, forensic toxicology and pharmaceutical research analysis. The Company also believes that the technologies of LC/MS/MS and GC/MS/MS will replace our current dependence on LC, GC and simple GC/MS as ICP/MS has now largely replaced our previous dependence on atomic absorption. 5. Research and Development. The markets for laboratory testing and clinical diagnostic products are highly competitive, and innovations and technological changes occur frequently. For these reasons, the Company has devoted substantial funds to research and development of its products and services. During the fiscal years ended December 31, 1996, 1995 and 1994, the Company incurred expenses of $1,280,000, $920,000, and $729,000 respectively, for research and development. As of December 31, 1996, the Company employed 12 people in research and development, 9 of whom hold Ph.D.'s. 6. Raw Materials. The raw materials required by the laboratory for urine drug testing consist primarily of two types: specimen collection supplies and reagents for laboratory analysis. The collection supplies include Drug Testing Custody and Control Forms that identify the specimen and the client, as well as document the chain-of-custody. Collection supplies also consist of specimen bottles and shipping boxes. Reagents for drug testing are primarily immunoassay screening products and various chemicals used for confirmation testing. The Company believes all of these materials are available at competitive prices from other suppliers. The primary raw materials required for the immunoassay-based test kits produced by the Company consist of antibodies, antigens and other reagents, plastic injection-molded devices, glass fiber, nitrocellulose filter materials, and packaging materials. The Company maintains an inventory of raw materials which, to date, has been acquired primarily from third parties. Currently, most raw materials are available from several sources. The Company possesses the technical capability to produce its own antibodies and has initiated production of antibodies for certain tests. However, if the Company were to change its source of supply for raw materials used in a specific test, additional development, and the accompanying costs, may be required to adapt the alternate material to the specific diagnostic test. 7. Patents, Trademarks, Licensing and Other Proprietary Information. The Company holds nine issued United States patents, eight of which generally form the basis for the EZ-SCREEN and one-step technologies. Additionally, the Company has one patent which relates to methods of utilizing whole blood as a sample medium on its immunoassay devices. The Company also holds various patents in several foreign countries. The Company also holds two United States patents which it acquired in the acquisition of Granite Technological Enterprises, Inc. in 1986. Of the eight U.S. patents mentioned above which generally form the basis for the EZ-SCREEN and one-step technologies, one expires in 2000, one expires in 2004, five expire in 2007, and one expires in 2010. The patent which relates to the methods of utilizing whole blood as a sample medium expires in 2012. There can be no guarantee that there will not be a challenge to the validity of the patents. In the event of such a challenge, the Company might be required to spend significant funds to defend its patents, and there can be no assurance that the Company would be successful in any such action. The Company believes that the basic technologies requisite to the production of antibodies are in the public domain and are not patentable. The Company intends to rely upon trade secret protection of certain proprietary information, rather than patents, where it believes disclosure could cause the Company to be vulnerable to competitors who could successfully replicate the Company's production and manufacturing techniques and processes. The Company holds approximately 15 registered trade names and/or trademarks in reference to its products and corporate names. The trade names and/or trademarks of the Company range in duration from 10 years to 20 years with expiration dates ranging from 2001 to 2008. Applications have also been made for additional trade names. 8. Seasonality. The Company believes that the laboratory testing business is subject to seasonal fluctuations in pre-employment screening which has low points in July and December annually. The Company does not believe that seasonality is a significant factor in sales of its on-site immunoassay tests. However, the Company believes that sales of certain of its tests for the agricultural markets such as its EZ-SCREEN:AFLATOXIN test coincide with the harvesting of crops meant for human and animal consumption. 9. Backlog. At December 31, 1996, the Company did not have any significant backlog and normally does not have any significant backlog. The Company does not believe that recorded sales backlog is a significant factor in its business. 10. Competition. Laboratory Services. Competition in the area of drugs of abuse testing is intense. Competitors and potential competitors include forensic testing units of large clinical laboratories, such as Laboratory Corporation of America Holdings, Quest Diagnostics, Inc. and SmithKline Laboratories, Inc. and other independent laboratories, other specialized laboratories, and in-house testing facilities maintained by hospitals. Competitive factors include reliability and accuracy of tests, price structure, service, transportation collection networks and the ability to establish relationships with hospitals, physicians, and users of drug abuse testing programs. It should be recognized, however, that many of the competitors and potential competitors have substantially greater financial and other resources than the Company. The industry in which the Company competes is characterized by service issues including, turn-around time of reporting results, price, the quality and reliability of results, and an absence of patent or other proprietary protection. In addition, since tests performed by the Company are not protected by patents or other proprietary rights, any of these tests could be performed by competitors. However, there are proprietary assay protocols for the more specialized testing that are unique to the Company. Some specific segments of the laboratory testing business are price competitive with low margins. Other segments, which place a premium on quality, constitute a large part of the business of MEDTOX, where, to date, quality service has been a more important competitive factor than price. This has allowed MEDTOX to generate positive gross margins. The Company's ability to successfully compete in the future and maintain it margins will be based on its ability to maintain its quality and customer service strength while maintaining efficiencies and low cost operations. There can be no assurance that price competitiveness will not increase in importance as a competitive factor in the business of MEDTOX. Immunoassay Tests. The diagnostics market has become highly competitive with respect to the price, quality and ease of use of various tests and is characterized by rapid technological and regulatory changes. The Company has designed its on-site tests as inexpensive, on-site tests for use by unskilled personnel, and has not endeavored to compete with laboratory-based systems. Numerous large companies with greater research and development, marketing, financial, and other capabilities, as well as government-funded institutions and smaller research firms, are engaged in research, development and marketing of diagnostic assays for application in the areas for which the Company produces its products. The Company has experienced increased competition with respect to its immunoassay tests from systems and products developed by others, many of whom compete solely on price. As the number of firms marketing diagnostic tests has grown, the Company has experienced increased price competition. A further increase in competition may have a material adverse effect on the business and future financial prospects of the Company. 11. Government Regulations. The products and services of the Company are subject to the regulations of a number of governmental agencies as listed below. It is believed that the Company is currently in compliance with all regulatory authorities. The Company cannot predict whether future changes in governmental regulations might significantly increase compliance costs or adversely affect the time or cost required to develop and introduce new products. In addition, products of the Company are or may become subject to foreign regulations. 1. United States Food and Drug Administration (FDA). Certain tests for human diagnostic purposes must be cleared by the FDA prior to their marketing for in vitro diagnostic use in the United States. The FDA regulated products produced by the Company are in vitro diagnostic products subject to FDA clearance through the 510(k) process which requires the submission of information and data to the FDA that demonstrates that the device to be marketed is substantially equivalent to a currently marketed device. This data is generated by performing clinical studies comparing the results obtained using the Company's device to those obtained using an existing test product. Although no maximum statutory response time has been set for review of a 510(k) submission, as a matter of policy the FDA has attempted to complete review of 510(k) submissions within 90 days. To date, the Company has received 510(k) clearance for 11 different products and the average time for clearance was 72 days with a maximum of 141 days and a minimum of 20 days. Products subject to 510(k) regulations may not be marketed for in vitro diagnostic use until the FDA issues a letter stating that a finding of substantial equivalence has been made. As a registered manufacturer of FDA regulated products, the Company is subject to a variety of FDA regulations including the Good Manufacturing Practices (GMP) regulations which define the conditions under which FDA regulated products are to be produced. These regulations are enforced by FDA and failure to comply with GMP or other FDA regulations can result in the delay of premarket product reviews, fines, civil penalties, recall, seizures, injunctions and criminal prosecution. 2. Health Care Financing Administration (HCFA). The Clinical Laboratory Improvement Act (CLIA) introduced in 1992 requires that all in vitro diagnostic products be categorized as to level of complexity. A request for CLIA categorization of any new clinical laboratory test system must be made simultaneously with FDA 510(k) submission. The EZ-SCREEN and VERDICT drugs of abuse tests currently marketed by EDITEK have been categorized as moderately complex. The complexity category to which a clinical laboratory test system is assigned may limit the number of laboratories qualified to use the test system thus impacting product sales. The MEDTOX laboratory is a CLIA licensed laboratory. 3. United States Department of Defense (DOD). As a result of the Company's contract with the DOD being classified as Secret, it has been necessary to establish the appropriate security procedures and facilities, including designation of a Facility Security Officer who is responsible for overseeing the security system, including conduct of periodic security audits by appropriate defense agencies. Additionally, the Company is now subject to periodic audits of its accounting systems and records by the Defense Audit Agency. 4. Drug Enforcement Administration (DEA). The primary business of the Company involves either testing for drugs of abuse or developing test kits for the detection of drugs/drug metabolites in urine. MEDTOX is registered with the DEA to conduct chemical analyses with controlled substances. The EDITEK facility in Burlington, N.C. is registered by the DEA to manufacture and distribute controlled substances and to conduct research with controlled substances. Maintenance of these registrations requires that the Company comply with applicable DEA regulations. 5. Substance Abuse and Mental Health Services Administration (SAMHSA). MEDTOX has been certified by SAMHSA since 1988. SAMHSA certifies laboratories meeting strict standards under Subpart C of Mandatory Guidelines for Federal Workplace Drug Testing Programs. Continued certification is accomplished through periodic inspection by SAMHSA to assure compliance with applicable regulations. 6. Additional Laboratory Regulations. The MEDTOX laboratories and certain of the laboratory personnel are licensed or otherwise regulated by certain federal agencies, states, and localities in which MEDTOX conduct business. Federal, state and local laws and regulations require MEDTOX, among other things, to meet standards governing the qualifications of laboratory owners and personnel, as well as the maintenance of proper records, facilities, equipment, test materials, and quality control programs. In addition, both laboratories are subject to a number of other federal, state, and local requirements which provide for inspection of laboratory facilities and participation in proficiency testing, as well as govern the transportation, packaging, and labeling of specimens tested by either laboratory. The laboratories are also subject to laws and regulations prohibiting the unlawful rebate of fees and limiting the manner in which business may be solicited. MEDTOX receives and uses small quantities of hazardous chemicals and radioactive materials in their operations and are licensed to handle and dispose of such chemicals and materials. Any business handling or disposing of hazardous and radioactive waste is subject to potential liabilities under certain of these laws. 12. Product and Professional Liability. Manufacturing and marketing of products by the Company entail a risk of product liability claims. In August, 1993, the Company procured insurance coverage against the risk of product liability arising out of events after such date, but such insurance does not cover claims made after that date based on events that occurred prior to that date. The insurance policy covers damages that the Company is legally obligated to pay as a result from bodily injury and property damage. Consequently, for uncovered claims, the Company could be required to pay any and all costs associated with any product liability claims brought against it, the cost of defense whatever the outcome of the action, and possible settlement or damages if a court rendered a judgment in favor of any plaintiff asserting such a claim against the Company. Damages may include punitive damages, which may substantially exceed actual damages. The obligation to pay such damages could have a material adverse effect on the Company and exceed its ability to pay such damages. No product liability claims are pending. The Company's laboratory testing services are primarily diagnostic and expose the Company to the risk of liability claims. The Company's laboratories have maintained continuous Professional and General Liability insurance since 1985. The insurance policy covers those amounts the Company is legally obligated to pay from damages resulting from a Medical Incident, which arises out of a Failure to Render Professional Services. To date, the Company has not had any substantial product liability and no material professional service claims are currently pending. 13. Employees. As of December 31, 1996, the Company had a total of 320 full time employees as compared to a total of 106 full time employees at December 31, 1995. Of the 320 full time employees, 292 work at and for MEDTOX, while the remaining 28 work at the Company's facility in Burlington, N.C. Of the 292 full time employees of MEDTOX, 223 were involved in laboratory operations, 11 were involved in sales and marketing, 7 were involved in research and development, and 22 were involved in administrative and clerical functions at December 31, 1996. In addition 6 of the full time employees at MEDTOX hold doctorate degrees. Of the 28 full time employees at the Company's facility in Burlington, N.C. 16 were involved in manufacturing and distribution, 5 were involved in research and product development, and 7 in administrative and clerical functions at December 31, 1996. Additionally, 4 of the employees in Burlington, N.C. hold doctorate degrees. The Company's employees are not covered by any collective bargaining agreements, and the Company has not experienced any work stoppages and the Company considers its relations with its employees to be good. ITEM 6. SELECTED FINANCIAL DATA. The following selected financial data are derived from financial statements of the Company and should be read in conjunction with the financial statements, related notes, and other financial information included herein.
Years Ended December 31 1996 1995 1994 1993 1992 ----- ------ -------- ----- ------ (in thousands, except per share amounts) Net revenues $26,726 $7,526 $6,593 $2,633 $2,989 Net loss (12,809) (7,285) (3,546) (3,066) (1,292) Preferred stock deemed dividend 6,783 -0- -0- -0- -0- Net loss applicable to common stockholders (19,592) (7,285) (3,546) (3,066) (1,292) Net loss per share applicable to common stockholders (0.59) (0.77) (0.49) (0.56) ( .35) Total assets 24,079 3,938 7,378 4,005 3,188 Long term debt -0- -0- 63 -0- 113 Cash dividends -0- -0- -0- -0- -0-
ITEM 7. MANAGEMENT'S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS. General The Company commenced operations in June 1983 and until 1986 was a development stage company. The Company became engaged in the manufacture and sale of culture media, animal blood products, customer antisera, and other Conventional Biodiagnostic Products as a result of its acquisition of Granite Technological Enterprises, Inc. in June 1986. The Company began the manufacture and sale of its EZ-SCREEN diagnostic tests in 1985 and introduced its patented one-step assay, VERDICT and RECON, in 1993. In February 1994, the Company completed the acquisition of PDLA. In June 1995, the Company completed the acquisition of Bioman Products and in January 1996, the Company completed the acquisition of MEDTOX. The results of operations for the year ended December 31, 1996 include the results of operations of MEDTOX for the period January 30, 1996 through December 31, 1996. Since inception, the Company has financed its working capital requirements primarily from the sale of equity securities. Year Ended December 31, 1996 Compared to Year Ended December 31, 1995 Total revenues for the year ended December 31, 1996 were $26,726,000 as compared to $7,526,000 for the year ended December 31, 1995. The increase was attributable to the increase in revenues from products and services. These revenues totaled $26,498,000 for the year ended December 31, 1996 as compared to $7,037,000 for the prior year. Laboratory service revenues were $23,541,000 for the year ended December 31, 1996, compared to $4,312,000 for the year ended December 31, 1995. This increase was due to the revenues contributed by the MEDTOX customer base. The revenues generated by MEDTOX for the period February 1, 1995 through December 31, 1995 were $18,791,000 providing for pro forma comparable laboratory service revenues for the year ended December 31, 1995 of $23,103,000 as compared to the $23,541,000 of revenues realized from the sales of laboratory services for the year ended December 31, 1996. Included in product sales are the sales generated from substance abuse testing products, which incorporates the EZ-SCREEN and VERDICT on-site test kits and other ancillary products for the detection of abused substances. Sales from these products were $1,471,000 for the year ended December 31, 1996 compared to $1,180,000 recorded for the year ended December 31, 1995. This increase of 25% was primarily the result of sales of the EZ-SCREEN PROFILE test kits which were introduced in May of 1996, as well as increased sales of the VERDICT test kits. Product sales also include sales of diagnostic products for the agricultural market. Sales of these products were $1,110,000 for the year ended December 31, 1996 as compared to $1,090,000 for the year ended December 31, 1995. Sales of other products, including contract manufacturing services were $301,000 for the year ended December 31, 1996. Sales of these products and services were $393,000 for the year ended December 31, 1995. The decrease of 23% was primarily the result of the Company's decision not to market these products. Accordingly, the Company closed down the operations of its farm facility during 1996. While the closure will decrease the amount of revenues generated from these sales, the elimination of the costs of the farm facility are expected to improve the overall gross margin. The Company does, however, intend to pursue additional contract manufacturing contracts. Revenues generated from the shipments of products to the U.S. Department of Defense were $75,000 for the year ended December 31, 1996 as compared to $62,000 for the year ended December 31, 1995. Revenues from royalties and fees during the year ended December 31, 1996 were $90,000, compared to $300,000 for the year ended December 31, 1995. This decrease was primarily due to lower royalties from American Medical Laboratories, Inc. ("AML"), as AML lost accounts that required payment of royalties to the Company. Revenues from interest and other income for the year ended December 31, 1996 were $138,000 compared to $189,000 for the year ended December 31, 1995. The $189,000 in 1995 included the recovery of debts owed by a customer of laboratory services which had been written off, as well as a payment made to the Company by the landlord of the facility in New Jersey for renewing the lease for that facility. During 1996, there was no such payment or recovery of such debts. The gross margin from the revenues generated from the laboratory services was 35% for the year ended December 31, 1996 an increase compared to 1995, when the gross margin was 9%. The improvement in the gross margin was primarily due to the operations of MEDTOX and the consolidation of the laboratory operations of PDLA into the laboratory operations of MEDTOX. Gross margins from the sales of both manufactured products and products purchased for resale for the year ended December 31, 1996 were 27% compared to 18% of sales of these products during the year ended December 31, 1995. This increase in gross margin from product sales is primarily the result of the increased sales of contract manufacturing services, sales of the EZ-SCREEN PROFILE test kits, as well as sales of the agricultural products sold through DIAGNOSTIX. Selling, general and administration expenses for the year ended December 31, 1996 were $11,725,000, compared to $4,630,000 for the year ended December 31, 1995. Of the $7,095,000 increase, MEDTOX related expenses totaled $6,568,000. Net of MEDTOX, there was an increase of $527,000 compared to the same period in 1995. This increase is primarily due to $1,161,000 of amortization expense related to goodwill resulting from the MEDTOX acquisition. In addition, the Company has expensed in excess of $1,000,000 for legal fees during the year ended December 31, 1996. These legal fees are primarily for expenses relating to the Company's inability to issue shares to certain of the Series A Preferred Shareholders. Research and development expenses incurred during the year ended December 31, 1996 were $1,280,000 as compared to $920,000 for the same period in 1995. This increase of $360,000 was primarily the result of $398,000 of research and development expenses from MEDTOX as well as increases in personnel costs. For the year ended December 31, 1996, EDITEK incurred interest expense of $469,000, compared to interest expense of $23,000 incurred during the year ended December 31, 1995. This increase was the result of the funds borrowed by the Company to complete the financing for the acquisition of MEDTOX. In connection with the acquisition of MEDTOX, the Company determined that it would be beneficial to consolidate the laboratory operations of PDLA into the laboratory operations at MEDTOX as well as to down size certain administrative positions at both PDLA and MEDTOX in order to eliminate duplicative functions. The Company also determined that to improve the operating results of the Company, it would be necessary to sell the former operations of Bioman, close its farm facility and reduce its work force at its Burlington, North Carolina location. As a result of these restructuring steps, the Company has taken charges of $2,449,000 during the year ended December 31, 1996 to cover certain costs of the restructurings, including $907,000 related to certain severance payments (see Note 8 of the Financial Statements). The Company had no such charge during the year ended December 31, 1995. As previously reported, the Company has undertaken a review of the value of the goodwill associated with the acquisition of MEDTOX in 1996. The purpose of the review was to determine if the value of the goodwill, generated as a result of the price paid by the Company for MEDTOX, was in fact supported by the projected future benefit to the Company as measured by generated cash flow. Given the highly competitive nature of the testing marketplace, the industry is undergoing, and MEDTOX has begun to experience, a declining average selling price. The Company expects this trend to continue. In addition, the Company expects that alternative testing methods, including on-site testing, are available or may become available in future years that may make the current forms of laboratory testing less competitive. While the Company expects to continue to develop and/or evaluate new testing technologies, the current form of laboratory testing at MEDTOX could not support the carrying value of the goodwill from the sale of that laboratory to the Company. Utilizing an undiscounted cash flow analysis, the Company determined that the carrying value of the remaining goodwill associated with the MEDTOX acquisition exceeded the estimated cash flows. Accordingly, the Company recorded a write-off of $6,016,000 at December 31, 1996. The noncash write-off of the goodwill will reduce the future amortization expense of the Company by $317,000 per year. At December 31, 1995, the Company recorded a write-off of $3,073,000 of the goodwill associated with the acquisition of PDLA. As a result of the above, the net loss for the year ended December 31, 1996 was $12,809,000 compared to the net loss of $7,285,000 for the year ended December 31, 1995. In March 1997, the Securities and Exchange Commission Staff (the "Staff") announced its position on accounting for preferred stock which is convertible into common stock at a discount from the market rate at the date of issuance. To comply with this position, the Company restated its loss for the year ended December 31, 1996 applicable to common stockholders to reflect a deemed dividend of $6,783,000 related to the January 1996 sales of the Series A Preferred Stock. The restatement resulted in an increase in the previously reported net loss applicable to common stockholders from the previously reported $12,809,000 to $19,592,000 for the year ended December 31, 1996. The Company had no such charge for the year ended December 31, 1995. Management believes the acquisition of MEDTOX and the restructuring of the laboratory operations will significantly improve the operating results of the Company although there can be no assurance of the success of the consolidation of the laboratory operations in reducing costs and improving efficiencies. Management expects net sales to grow through both the addition of new accounts, through increased selling efforts, as well as the introduction of new products and services, such as additional on-site tests and additional laboratory tests. The Company will also continue to pursue strategic acquisitions to increase sales. Year Ended December 31, 1995 Compared to Year Ended December 31, 1994 Total revenues for year ended December 31, 1995 increased 14% to $7,526,000, compared to $6,593,000 for the prior year. This increase is primarily fully attributable to the increase in revenues from sales of products and services for 1995. These revenues totaled $7,037,000, an increase of 14% compared to $6,183,000 for the prior year. Laboratory Service Revenues for the year ended December 31, 1995 were $4,312,000, an 18% increase compared to $3,647,000 for the prior year. This increase was due primarily to the efforts of a full sales and marketing force for the laboratory services of PDLA. During the year ended December 31, 1994, the company realized sales of $566,000 from laboratory services that were transferred to American Medical Laboratories, Inc. ("AML") in January 1995 and, as such, are not included in the sales for the year ended December 31, 1995. Accordingly, the increase in Laboratory Service revenue excluding those sales transferred to AML was actually $1,231,000. Product sales include the sales generated from substance abuse testing products, which incorporates the EZ-SCREEN and VERDICT on site tests and other ancillary products for the detection of abused substances. Sales from these products were $1,180,000, down 9% compared to $1,293,000 for the prior year. The Company believes this decrease was primarily due to increased competition. This competition was caused by the introduction of several products by competitors which compete with the products of the Company. The decrease was also affected by the lack of a complete product line of the VERDICT products. Product sales also include sales of agricultural diagnostic products which are marketed through diAGnostix, inc. Sales of these products were $1,090,000 for the year ended December 31, 1995, an increase of 35% compared to sales of $805,000 for the prior year. The acquisition of Bioman Products Inc. on June 1, 1995 brought $404,000 in sales revenues to the Company for the year ended December 31, 1995. Excluding these revenues, sales of agricultural diagnostic products were $686,000 for 1995, a decrease of 15% compared to 1994. The Company believes this decrease is due to decreased testing by customers of the Company. Sales of Microbiological and associated product sales and contract manufacturing services were $393,000 for the year ended December 31, 1995, down 10% compared to $438,000 for these products and services in 1994. This decrease was due to a reduced marketing effort. In 1995, the Company completed research and development on certain tests developed for the U.S. Department of Defense. This enabled production to begin for the first time on products specifically manufactured for the U.S. Department of Defense. Revenues from shipment of these products were $62,000 for the year ended December 31, 1995. Revenues from royalties and fees during the year ended December 31, 1995 were $300,000, compared to $200,000 for 1994. This increase was primarily due to the royalties received from AML pursuant to the agreement the Company has with AML. Revenues from interest and other income for the year ended December 31, 1995 were $189,000, compared to $210,000 for the year ended December 31, 1994. The overall gross margin from sales for the year ended December 31, 1995 was 6%, compared to 2% of sales for the year ended December 31, 1994. Gross margins from the sales of both manufactured and products purchased for resale for the year ended December 31, 1995 were 18% compared to 16% of sales of these products for the year ended December 31, 1994. An increase in the number of samples being processed at PDLA resulted in improved gross margins for laboratory services for the year ended December 31, 1995. For the year ended December 31, 1995, the gross margin was 9% as compared to 2% for the year ended December 31, 1995. Since a large amount of the costs of providing laboratory services are fixed or near fixed costs, the margins from sales of laboratory services are volume dependent. Selling, general and administrative expenses for the year ended December 31, 1995 were $4,630,000, compared to $3,674,000 for the year ended December 31, 1994. This increase of 26% was primarily a result of increased sales and marketing expenses associated with the sale of the Substance Abuse Testing Products and Services marketed through PDLA, the sales and marketing costs associated with former operations of Bioman, as well as overall increases in the general expenditures resulting from the acquisition of PDLA. Research and development expenses incurred during the year ended December 31, 1995 were $920,000, as compared to $729,000 for the year ended December 31, 1994. This 26% increase was primarily due to increased personnel costs and expenses, as well as increases in work being performed pursuant to the DOD contract. For the year ended December 31, 1995, the Company incurred interest expense of $23,000, compared to interest expense of $25,000 incurred during the year ended December 31, 1994. The continued operating losses and negative cash flows in 1995 of the PDLA operations resulted in an evaluation at year end of the PDLA goodwill for possible impairment. The Company determined that the operations of PDLA did not have long-term future viability as a stand-alone laboratory operation and would not be supported by the Company on a stand-alone basis. The underlying factors contributing to the financial results for PDLA include competitive pricing pressures in the marketplace and the inability of the Company to generate sufficient PDLA business volume that would result in positive cash flows and profitable operations as a stand-alone laboratory operation. The Company performed an analysis of the PDLA undiscounted cash flows and projected that PDLA would have negative cash flows for the foreseeable future. The Company determined that the estimated shortfall of cash flows exceeded the carrying value of the remaining PDLA goodwill, and as a result, recorded a write-off of $3,073,000 at December 31, 1995. The noncash write-off of goodwill will reduce the future amortization expense of the Company by $173,000 per year. As a result of the above, the net loss for the year ended December 31, 1995 was $7,285,000 compared to the net loss of $3,546,000 for the year ended December 31, 1994. Material Changes in Financial Condition At December 31, 1996, cash and cash equivalents were $82,000 compared to $258,000 as of December 31, 1995. At December 31, 1996, net accounts receivable were $4,553,000. This $3,524,000 increase compared to $1,029,000 at December 31, 1995 was primarily due to the MEDTOX accounts receivable balance at December 31, 1996. Inventories were $1,290,000 at December 31, 1996 compared to $937,000 at December 31, 1995. This increase of $353,000 or 38% was primarily due to the inventory balance of MEDTOX at December 31, 1996. Prepaid expenses and other assets were $140,000 at December 31, 1996, as compared to $868,000 at December 31, 1995. This decrease of $728,000 was primarily the result of the January 1996 application of the $500,000 deposit the Company had previously made towards the purchase price for the acquisition of MEDTOX. As of December 31, 1996, the Company had a balance of accounts payable of $2,387,000 compared to a balance of $1,184,000 at December 31, 1995. The increase of $1,203,000 was net of an increase due to accounts payable of MEDTOX and a decrease in past due expenses resulting from the Company's improved financial condition. Accrued expenses were $2,074,000 at December 31, 1996, as compared to $834,000 at December 31, 1995. Of the total increase of $1,240,000, the accrued expenses from MEDTOX were $1,155,000 at December 31, 1996. As of December 31, 1996, the Company had accrued $1,100,000 for the payment of certain restructuring costs associated with the consolidation of the laboratory of PDLA with the laboratory operations of MEDTOX as well as costs associated with certain actions taken by the Company including a reduction in work force during the year ended December 31, 1996. In addition, MEDTOX has accrued $703,000 for the payment of a lease obligation for a facility no longer used by MEDTOX. As a result, the Company has a total balance accrued restructuring costs of $1,803,000 at December 31, 1996. At December 31, 1995, the Company had no accrual for restructuring costs. During the year ended December 31, 1996, the Company repaid the $100,000 it had borrowed from Dr. Samuel C. Powell, a director of the Company as well as the balance of the loan payable to the North Carolina Biotechnology Center. At December 31, 1996, the Company had a total balance of $4,227,000 for its loan payable to its institutional lender. At December 31, 1995, the Company had total loans payable of $182,000. Liquidity and Capital Resources Since its inception, the working capital requirements of the Company have been funded by cash received from equity investments in the Company. At December 31, 1996, the Company had cash and cash equivalents of $82,000. To finance the acquisition of MEDTOX and provide working capital, the Company raised $20,350,000 from the sale of 407 shares of Series A Preferred Stock and borrowed $5,000,000. The debt financing consists of two term loans totaling $4,000,000 and up to $7,000,000 in the form of a revolving line of credit based primarily on the receivables of the Company (the "Loan Agreement"). The amount of credit available to the Company varies with the accounts receivable and the inventory of the Company. The interest rates on the two term loans of $2,000,000 each are 2.5 points above the prime rate and 2.0 points above the prime rate. The revolving line of credit carries an interest rate equal to 1.5 points above the prime rate. The Company believes that the aforementioned capital will be sufficient to fund the Company's planned operations through 1997, although there can be no assurance that the available capital will be sufficient to fund the future operations of the Company beyond 1997. As of December 31, 1996, the Company had not achieved a positive cash flow from operations. Accordingly, the Company relies on available credit arrangements, outside funding of research and development, and continued sales of its equity securities to fund operations until a positive cash flow can be achieved. Management believes that it has taken, and is prepared to continue to take, the actions required to yield a positive cash flow from operations in the future. The Company believes that the acquisition of MEDTOX, the consolidation of the laboratory operations from PDLA to MEDTOX, and other synergies that will be realized from the acquisition of MEDTOX will enable the Company to generate positive cash flow. The Company continues to follow a plan which includes (i) continuing to aggressively monitor and control costs, (ii) increasing revenue from sales of the Company's products, services, and research and development contracts, as well as (iii) pursuing synergistic acquisitions to increase the Company's critical mass. There can be no assurance that costs can be controlled, revenues can be increased, financing may be obtained, acquisitions successfully consummated, or that the Company will be profitable. ITEM 8. FINANCIAL STATEMENTS AND SUPPLEMENTARY DATA. Reference is made to the financial statements, financial statement schedules and notes thereto included later in this report under Item 14. PART IV ITEM 14 - EXHIBITS, FINANCIAL STATEMENT SCHEDULES, REPORTS ON FORM 8-K. a. (i) Financial Statements Page Report of Independent Auditors......... 33 Consolidated Balance Sheets at December 31, 1996 and 1995.................... 34 Consolidated Statements of Operations for the years ended December 31, 1996, 1995 and 1994.................. 36 Consolidated Statements of Stockholders' Equity for the years ended December 31, 1996, 1995 and 1994........................ 37 Consolidated Statements of Cash Flows for the years ended December 31, 1996, 1995 and 1994..... 38 Notes to Consolidated Financial Statements........................... 40 Report of Independent Auditors The Board of Directors EDITEK, Inc. We have audited the accompanying consolidated balance sheets of EDITEK, Inc. as of December 31, 1996 and 1995, and the related consolidated statements of operations, stockholders' equity and cash flows for each of the three years in the period ended December 31, 1996. Our audits also included the financial statement schedule listed in the Index at Item 14(a). These consolidated financial statements and schedule are the responsibility of the Company's management. Our responsibility is to express an opinion on these consolidated financial statements and schedule based on our audits. We conducted our audits in accordance with generally accepted auditing standards. Those standards require that we plan and perform the audit to obtain reasonable assurance about whether the financial statements are free of material misstatement. An audit includes examining, on a test basis, evidence supporting the amounts and disclosures in the financial statements. An audit also includes assessing the accounting principles used and significant estimates made by management, as well as evaluating the overall financial statement presentation. We believe that our audits provide a reasonable basis for our opinion. In our opinion, the consolidated financial statements referred to above present fairly, in all material respects, the consolidated financial position of EDITEK, Inc. at December 31, 1996 and 1995, and the result of its operations and its cash flows for each of the three years in the period ended December 31, 1996, in conformity with generally accepted accounting principles. Also, in our opinion, the related financial statement schedule, when considered in relation to the consolidated financial statements taken as a whole, presents fairly in all material respects the information set forth therein. /s/ Ernst & Young LLP Minneapolis, Minnesota February 21, 1997, except for Note 12 as to which the date is July 18, 1997 EDITEK, Inc. Consolidated Balance Sheets (In thousands, except for number of shares)
December 31 1996 1995 Assets Current assets: Cash and cash equivalents $ 82 $ 258 Accounts receivable: Trade, less allowance for doubtful accounts (1996--$358; 1995-- $130) 4,476 977 Other 77 52 -------------------------------- 4,553 1,029 Inventories: Raw materials 488 588 Work in process 146 169 Finished goods 656 180 --------------------------------- 1,290 937 Deposit on acquisition (Note 2) - 500 Prepaid expenses and other 140 368 ---------------------------------- Total current assets 6,065 3,092 Equipment and improvements: Furniture and equipment 9,200 5,857 Leasehold improvements 929 1,696 ---------------------------------- 10,129 7,553 Less accumulated depreciation and amortization (7,951) (6,824) ---------------------------------- 2,178 729 Goodwill, net of accumulated amortization of $1,184 in 1996 and $7 in 1995 (Notes 2 and 3) 15,836 117 ---------------------------------- Total assets $ 24,079 $3,938 =================================
December 31 1996 1995 Liabilities and stockholders' equity Current liabilities: Line of credit (Note 4) $ 1,437 $ - Accounts payable 2,387 1,184 Accrued expenses 2,074 834 Current portion of restructuring accrual 899 - Current portion of long-term debt (Note 4) 2,790 82 Note payable to director - 100 Other current liabilities 40 42 -------------------------------- Total current liabilities 9,627 2,242 Long-term portion of restructuring accrual 904 - Stockholders' equity (Notes 5 and 6): Preferred Stock, $1.00 par value: Authorized shares - 1,000,000 Issued and outstanding shares - 238 in 1996 and -0- in 1995 - - Common Stock, $.15 par value: Authorized shares - 60,000,000 in 1996 and 30,000,000 in 1995 Issued and outstanding shares - 25,555,796 in 1996 and 10,439,775 in 1995 3,834 1,566 Additional paid-in capital 56,366 33,973 Accumulated deficit (46,476) (33,667) -------------------------------- 13,724 1,872 Less: Note receivable from stockholder - (100) Treasury stock (176) (76) -------------------------------- Total stockholders' equity 13,548 1,696 -------------------------------- Total liabilities and stockholders' equity $24,079 $ 3,938 ================================
See accompanying notes. EDITEK, Inc. Consolidated Statements of Operations
Year ended December 31 1996 1995 1994 (In thousands, except share and per share data) Restated Revenues: Laboratory service revenues $ 23,541 $ 4,312 $ 3,647 Product sales 2,957 2,725 2,536 Royalties and fees 90 300 200 Interest and other income 138 189 210 ------------------------------------------------------ 26,726 7,526 6,593 Costs and expenses: Cost of services 15,344 3,925 3,569 Cost of sales 2,151 2,240 2,142 Selling, general and administrative 11,725 4,630 3,674 Research and development 1,280 920 729 Interest and financing costs 469 23 25 Restructuring costs (Note 8) 2,449 - - Goodwill write-off (Note 3) 6,117 3,073 - ------------------------------------------------------ 39,535 14,811 10,139 ------------------------------------------------------ Net loss $(12,809) $ (7,285) $ (3,546) Less preferred stock deemed dividend 6,783 - - ------------------------------------------------------ Net loss applicable to common stockholders $(19,592) $ (7,285) $ (3,546) ====================================================== Loss per share applicable to common stockholders $(.59) $(.77) $(.49) ====================================================== Weighted average number of shares of common stock outstanding 33,455,867 9,445,707 7,204,244 ======================================================
See accompanying notes. EDITEK, Inc. Consolidated Statements of Stockholders' Equity
Note Additional Accumu- Receivable Preferred Stock Common Stock Paid-In lated from Treasury Shares Par Value Shares Par Value Capital Deficit Stockholder Stock Total ------------------------------------------------------------------------------------------- (In thousands, except for number of shares) Balances at December 31, 1993 6,069,231 $ 910 $25,262 $(22,836) $(100) $ (5) $3,231 Exercise of stock options and 23,019 4 43 - - - 47 warrants Stock issued for PDLA acquisition 1,167,729 175 3,803 - - - 3,978 Sale of stock 15,360 2 31 - - - 33 Private placement of common stock 800,000 120 993 - - - 1,113 Net loss - - - (3,546) - - (3,546) -------------------------------------------------------------------------------------------- Balances at December 31, 1994 8,075,339 1,211 30,132 (26,382) (100) (5) 4,856 Exercise of stock options and 156,347 23 170 - - - 193 warrants Stock issued for Bioman acquisition 21,489 3 58 - - - 61 Sale of stock 12,037 2 25 - - - 27 Stock issued for conversion of debt 16,100 3 59 - - - 62 Purchase of treasury stock - - - - - (71) (71) Private placement of common stock 2,158,463 324 3,529 - - - 3,853 Net loss - - - (7,285) - - (7,285) ------------------------------------------------------------------------------------------- Balances at December 31, 1995 - $ - 10,439,775 1,566 33,973 (33,667) (100) (76) 1,696 Exercise of stock options and - - 100,422 15 31 - - - 46 warrants Stock issued for Medtox acquisition - - 2,517,306 378 4,447 - - - 4,825 Sale of preferred stock 407 - - - 19,126 - - - 19,126 Cancellation of note receivable from officer in exchange for common stock - - - - - - 100 (100) - Sale of stock - - 76,483 12 52 - - - 64 Conversion of preferred stock to common stock (169) - 12,186,515 1,828 (1,828) - - - - Private placement of common stock - - 235,295 35 565 - - - 600 Net loss - - - - - (12,809) - - (12,809) ------------------------------------------------------------------------------------------- Balances at December 31, 1996 238 $ - 25,555,796 $3,834 $56,366 $(46,476) $ - $(176) $13,548 ===========================================================================================
See accompanying notes. EDITEK, Inc. Consolidated Statements of Cash Flows
Year ended December 31 1996 1995 1994 ----------------------------------------- (In thousands) Operating activities Net loss $(12,809) $(7,285) $(3,546) Adjustments to reconcile net loss to net cash used in operating activities: Depreciation and amortization 2,265 644 633 Goodwill write-off 6,117 3,073 - PDLA write-off 284 - - Provision for losses on accounts receivable 128 (54) 58 Provision for obsolete inventory 97 (13) 5 Gain on sale or retirement of equipment (42) - - Changes in operating assets and liabilities, net of acquisition: Accounts receivable (749) (22) 31 Inventories (87) (58) (306) Prepaid expenses and other 365 (589) (19) Accounts payable, accrued expenses and other 1,025 453 116 Deferred revenues (97) 3 (17) Restructuring accruals 1,072 - - Leases payable - (23) (37) ----------------------------------------- Net cash used in operating activities (2,431) (3,871) (3,082) Investing activities Purchase of equipment and improvements (1,118) (177) (505) Proceeds from sale of equipment 45 - - Acquisitions, net of cash acquired (19,630) (37) 89 ----------------------------------------- Net cash used in investing activities (20,703) (214) (416) Financing activities Net proceeds from sale of preferred stock 19,126 - - Net proceeds from sale of common stock 710 4,073 1,193 Purchase of treasury stock - (71) - Net proceeds from line of credit, term loans and notes payable 5,437 119 850 Principal payments on line of credit, term loans and notes payable (2,315) (883) - ----------------------------------------- Net cash provided by financing activities 22,958 3,238 2,043 ----------------------------------------- Decrease in cash and cash equivalents (176) (847) (1,455) Cash and cash equivalents at beginning of year 258 1,105 2,560 ----------------------------------------- Cash and cash equivalents at end of year $ 82 $ 258 $ 1,105 =========================================
EDITEK, Inc. Consolidated Statements of Cash Flows (continued) Supplemental Noncash Activities During 1996, the Company canceled the note receivable from an officer of $100,000 in exchange for 13,334 shares of common stock. In January 1996, the Company acquired Medtox Laboratories, Inc. The purchase price was $24 million, which included $19 million cash and the issuance of $5,000,000 in common stock (2,517,306 shares). During 1995, the Company issued $62,000 of common stock related to the conversion of debt and issued $61,000 of common stock in connection with the acquisition of Bioman. See accompanying notes. EDITEK, Inc. Notes to Consolidated Financial Statements December 31, 1996 1. Summary of Significant Accounting Policies The Company The consolidated financial statements include the accounts of EDITEK, Inc. ("EDITEK") and its wholly-owned subsidiaries, Medtox Laboratories, Inc. ("Medtox") and diAGnostix, Inc. (collectively referred to as "the Company"). EDITEK is engaged in the research, development and sale of products based upon enzyme immunoassay technology for the detection of antibiotic residues, mycotoxins, drugs of abuse and other hazardous substances. Medtox provides clinical testing services for the detection of substances of abuse and diAGnostix, Inc. distributes agridiagnostic and food safety testing products. All significant intercompany transactions and balances have been eliminated. Trade Accounts Receivable Sales are made to local, national and international customers including corporations, clinical laboratories, government agencies, medical professionals, law enforcement agencies and healthcare facilities. Concentration of credit risk is limited due to the large number of customers to which the Company sells its products and services. The Company extends credit based on an evaluation of the customer's financial condition and receivables are generally unsecured. The Company provides an allowance for doubtful accounts equal to the estimated losses expected to be incurred in the collection of accounts receivable. Inventories Inventories are valued at the lower of cost (first-in, first-out method) or market. At December 31, 1996 and 1995, the inventory included reserves of $109,000 and $12,000, respectively, for lower of cost or market and for obsolescence. Equipment and Improvements Equipment and improvements are stated at cost. Provisions for depreciation have been computed using the straight-line method to amortize the cost of depreciable assets over their estimated useful lives. Leasehold improvements are amortized over the lesser of the lease term or the economic useful lives of the improvements. EDITEK, Inc. Notes to Consolidated Financial Statements (continued) 1. Summary of Significant Accounting Policies (continued) Revenue Recognition Sales are recognized in the statement of operations when products are shipped or services are rendered. Research and Development Research and development expenditures are charged to expense as incurred. Income Taxes The Company uses the liability method of accounting for income taxes. Under this method, deferred tax assets and liabilities are determined based on differences between the financial reporting and tax bases of assets and liabilities and are measured using the enacted tax rates and laws that will be in effect when the differences are expected to reverse. Cash and Cash Equivalents Cash and cash equivalents include cash and highly liquid investments maturing within three months when purchased. Loss Per Share of Common Stock Loss per share of common stock amounts are based on the weighted average number of shares of common stock outstanding, as well as shares of common stock that would have been issued and outstanding in certain transactions had the Company had the necessary number of authorized shares of common stock. All other common stock equivalents, including convertible debt disclosed in Note 4, were anti-dilutive and therefore were not included in the computation of loss per share, for all periods presented. 1. Summary of Significant Accounting Policies (continued) Goodwill Goodwill is amortized on a straight-line basis over 20 years. The carrying value of goodwill is reviewed if the facts and circumstances suggest that it may be impaired. If this review indicates that goodwill will not be recoverable, as determined based on the undiscounted cash flows of the entity acquired over the remaining amortization period, the Company's carrying value of the goodwill is reduced by the estimated shortfall of cash flows (see Note 3). Use of Estimates The preparation of financial statements in conformity with generally accepted accounting principles requires management to make estimates and assumptions that affect the amounts reported in the financial statements and accompanying notes. Actual results could differ from those estimates. Impairment of Long-Lived Assets In March 1995, the Financial Accounting Standards Board issued Statement No. 121, "Accounting for the Impairment of Long-Lived Assets and for Long-Lived Assets to be Disposed of," which requires impairment losses to be recorded on long-lived assets used in operations when indicators of impairment are present and the undiscounted cash flows estimated to be generated by those assets are less than the assets' carrying amount. Statement 121 also addresses the accounting for long-lived assets that are expected to be disposed of. The Company adopted Statement 121 in 1996, with no impact on the consolidated financial statements. 1. Summary of Significant Accounting Policies (continued) Reclassifications Certain reclassifications have been made to the 1995 and 1994 financial statements to conform with the 1996 presentation. 2. Acquisitions In January 1996, the Company acquired Medtox, a toxicology laboratory located in St. Paul, Minnesota. The purchase price was $24 million, which included $19 million cash and the issuance of 2,517,306 shares of common stock. The acquisition was accounted for under the purchase method of accounting under which the Company recorded approximately $22 million of goodwill. The goodwill is being amortized over a period of 20 years (see Note 3). The Company financed the acquisition by issuing $19 million of convertible preferred stock and borrowing $4 million under two $2 million term loans. In connection with the acquisition, the Company entered into a revolving line of credit of up to $7 million for working capital purposes. The following unaudited pro forma information presents the combined results of operations of the Company and Medtox for the years ended December 31, 1996 and 1995, as if the acquisition had been consummated as of January 1, 1995. 1996 1995 ---------------- Revenues $ 27,926 $27,745 ================= Net loss $(12,953) $(4,459) ================= Net loss per share $(.39) $(.37) ================= 2. Acquisitions (continued) On June 1, 1995, the Company acquired Bioman Products, Inc. ("Bioman"), an environmental diagnostics company. The purchase price was $140,000, which included cash and the issuance of 21,489 shares of common stock. The acquisition was accounted for under the purchase method of accounting under which the Company recorded $117,000 of goodwill, which is being amortized over a period of 20 years. The consolidated results of operations for the year ended December 31, 1995 included the results of the Bioman operations from June 1, 1995 to December 31, 1995. In September 1996, the Company sold the Bioman operations to a company headed by former employees of the Company and Bioman. The Company acquired Princeton Diagnostics Laboratories of America, Inc. (PDLA) on February 11, 1994 by issuing 826,790 shares of its common stock in exchange for all of the outstanding shares of PDLA's stock. The total value of the exchange was $3,876,000. The acquisition was accounted for under the purchase method of accounting and the Company recorded goodwill of $3,394,000. Additional shares of common stock were subsequently issued to former major shareholders of PDLA through price protection agreements. The consolidated results of operations for the year ended December 31, 1994 include the results of the PDLA operations from February 12, 1994 to December 31, 1994 (see Note 3). 3. Goodwill Write-Off The Company has reviewed the value of the goodwill associated with the acquisition of Medtox in 1996. The purpose of the review was to determine if the value of the goodwill, generated as a result of the price paid by the Company for Medtox, was in fact supported by the projected future benefit to the Company as measured by generated cash flows. 3. Goodwill Write-Off (continued) Given the highly-competitive nature of the testing marketplace, the industry is undergoing and Medtox has begun to experience, a declining average selling price. The Company expects this trend to continue. In addition the Company believes that alternative testing methods, including on-site testing, are available or may become available in future years that may make the current forms of laboratory testing less competitive. While the Company expects to continue to develop and or evaluate new testing technologies, the current form of laboratory testing at Medtox cannot support the carrying value of the goodwill generated from the sale of that laboratory to the Company. Utilizing an undiscounted cash flow analysis, the Company concluded that the carrying value of the remaining goodwill associated with the Medtox acquisition exceeded the estimated future cash flows. Accordingly, the Company recorded a write-off of $6,016,000 at December 31, 1996. In September 1996, the Company recorded a write-off of the goodwill associated with the acquisition of Bioman of $101,000 as a result of the sale of Bioman in September 1996. The continued operating losses and negative cash flows of the PDLA operations resulted in an evaluation during the fourth quarter of 1995 of the PDLA goodwill for possible impairment. The Company determined that the operations of PDLA did not have long-term future viability as a stand-alone laboratory operation and would not be supported by the Company on a stand-alone basis. The underlying factors contributing to the financial results for PDLA include competitive pricing pressures in the market place, the loss of preacquisition customers and the inability of the Company to generate sufficient PDLA business volume that would result in positive cash flows and profitable operations. The Company performed an analysis of the PDLA undiscounted cash flows over the remaining amortization period and determined that the estimated shortfall of cash flows exceeded the carrying value of the remaining PDLA goodwill. As a result, the Company recorded a write-off of goodwill of $3,073,000 at December 31, 1995. 4. Debt On January 30, 1996, the Company entered into a loan agreement with a financial institution to help finance the acquisition of Medtox. The debt financing consists of two eighteen-month term loans of $2,000,000 each and a revolving line of credit. The two term loans and the revolving line of credit are secured by a lien on all equipment, inventory and receivables and, depending on the amount of such inventory, or receivables, up to $7,000,000 may be available for borrowing under the revolving line of credit. The two term loans bear interest at 2.5% and 2.0%, respectively, above the bank prime rate. The revolving line of credit bears interest at 1.5% above the prime rate. The interest rates in effect as of December 31, 1996 for the two term loans and the revolving line of credit were 10.75%, 10.25% and 9.75%, respectively. At December 31, 1996 $1,437,000 had been borrowed against the revolving line of credit. At December 31, 1996 the balance remaining on the term loans was $2,790,000. The carrying value of the term loans and revolving line of credit approximate fair value. As of December 31, 1996, the Company was not in compliance with certain financial covenants in its loan agreement including, but not limited to, tangible net worth, fixed charge coverage and interest coverage. Accordingly, the entire amount outstanding under the term loans has been classified as a current liability. The Company is currently negotiating with its financial institution to revise its covenants so that the Company is in compliance. On August 15, 1989, the Company entered into a long-term loan agreement with a state funded, non-profit organization whereby the Company borrowed an aggregate of $125,000 to fund the development cost of a test for Chlamydia, a sexually transmitted disease. The loan originally had an interest rate of seven and one half percent (7.5%) per annum with all principal and interest due on August 15, 1994. The Company amended the loan agreement on the due date and issued 16,100 shares of common stock during 1995 as repayment for $62,000 of the loan. The remaining principal, $63,000, carries an interest rate of nine percent (9%) per annum. This principal and interest was repaid in 1996. On December 18, 1995, the Company borrowed $100,000 from a Director at an interest rate of 10.5%. The Company repaid the principal and interest in February, 1996. Interest paid for all outstanding debt was $424,000, $19,000 and $9,000 for the years ended December 31, 1996, 1995 and 1994, respectively. 5. Stockholders' Equity The Company has sold its common stock in various private transactions as follows:
Number Of Price Net Shares Per Share Proceeds ----------------------------------------------------------- 1996 235,295 $2.55 $ 600,000 1995 2,158,463 $1.63 to $2.25 $3,853,000 1994 800,000 $1.01 to $2.03 $1,113,000
In January 1996 the Company sold 407 shares of Series A Preferred Stock at a price of $50,000 per share. Pursuant to the Conversion Right of each share of Series A Preferred Stock, each share may be converted to shares of common stock. The amount of common shares to be issued upon the exercise of the Conversion Right is derived by dividing (i) the purchase price of one share of Series A Preferred Stock, $50,000 by (ii) the lower of (x) $2.775 or (y) 75% of the Market Price of the Common Stock on the date the Conversion Right is exercised. The "Market Price" is defined as the daily average of the closing bid prices quoted on the American Stock Exchange for the five trading days immediately preceding the date the Conversion Right is exercised. At December 31, 1996 169 shares of Series A Preferred Stock had been converted into 12,186,515 shares of common stock. The market price of the Company's common stock was $3.50 on the date of issuance of the Series A Preferred Stock. The excess of the $3.50 market value at the date of issuance over the $2.65 initial conversion price of the Series A Preferred Stock ($6,783,333 in total) was recorded as a deemed preferred stock dividend at date of issuance, which increased the net loss available to holders of common stock in the calculation of net loss per share. At December 31, 1996 an additional 210 shares of Series A Preferred Stock had been presented for conversion pursuant to the Conversion Right. However no common shares had been issued due to unresolved issues between the Company and the Preferred Stockholders. Subsequent to year-end, certain issues were resolved resulting in the issuance of 17,658,387 shares of Common Stock. As part of the purchase price paid by the Company for the acquisition of Medtox the Company issued 2,517,306 shares of Common Stock. 5. Stockholders' Equity (continued) In connection with the issuance of the common shares the Company agreed that if after the Closing Date the market value of the Common Stock of the Company declines below approximately $1.98 per share, the Company will issue additional shares of Common Stock ("Additional Shares") to shareholders of Medtox who retain their shares of Common Stock through specified dates (the "Repricing Dates") to compensate the Medtox shareholders for decreases after the closing of the Medtox transaction in the market price of the Common Stock of the Company below approximately $1.98 per share. The first of four (4) Repricing Dates was May 23, 1996. On May 23, 1996, the market price was $1.56 per share. Accordingly, 1,119,057 shares of Common Stock were issuable to the Medtox shareholders. The second Repricing Date was November 22, 1996 on which date the market price was $.95 per share. Accordingly an additional 1,293,458 shares of Common Stock were issuable to the Medtox shareholders. Subsequent to year-end, these 2,412,515 shares were issued. Because the number of Additional Shares that may become issuable is tied to decreases in the market price of the Common Stock, the number of Additional Shares issuable after December 31, 1996 to the Medtox shareholders cannot be determined at this time and will depend upon changes in the Market Price of the Common Stock, as well as the extent to which Medtox shareholders retain the Medtox shares on each of the Repricing Dates. 5. Stockholders' Equity (continued) At December 31, 1996, shares of common stock reserved for future issuance are as follows: Common stock warrants: Series K 50,000 Series L 320,000 Series M 10,550 Series N 32,679 Series O 586,667 Common stock options: Incentive 206,228 Non-Employee Director 228,310 Nonqualified 41,093 Qualified Employee Stock Purchase Plan 349,758 Equity Compensation Plan 2,998,333 Preferred stock convertible (estimated) 22,083,039 Price resets for Medtox transaction (estimated) 4,588,568 The conversion prices for the warrants range from $2.77 to $4.44, and the warrants expire in 1998 and 1999. 6. Stock Option and Purchase Plans The Company has stock option plans to provide incentives to eligible employees, officers, and directors in the form of incentive stock options, non-qualified stock options, stock appreciation rights, restricted and unrestricted stock awards, performance shares, and other stock-based awards. The Compensation Committee of the Board of Directors determines the exercise price (not to be less than the fair market value of the underlying stock) at the date of grant. Options generally become exercisable in installments over a period of one to five years and expire ten years from the date of grant. 6. Stock Option and Purchase Plans (continued) The following table summarizes information about stock options outstanding at December 31, 1996:
Plan Options Outstanding Weighted Non Average Shares Employee Exercise Available 1983 ISO 1993 Director Price for Grant Plan Plan Plan Share --------------- --------------------------------------------------------- Balance at December 31, 1993 3,702,146 483,240 23,000 70,094 $4.53 Granted (604,499) - 591,199 13,300 3.52 Canceled 180,492 (17,083) (167,192) (13,300) 4.75 Exercised - (4,500) - - 1.41 --------------- ------------------------------------------- Balance at December 31, 1994 3,278,139 461,657 447,007 70,094 3.35 Granted (300,742) - 300,742 - 3.19 Canceled 25,043 (12,251) (25,043) - 2.74 Exercised - - (1,667) (22,230) 0.60 --------------- ------------------------------------------- Balance at December 31, 1995 3,002,440 449,406 721,039 47,864 3.34 Additional shares reserved for issuance 350,000 - - - - Granted (238,300) - 225,000 13,300 2.83 Canceled 484,614 (153,986) (439,680) (44,934) 3.24 Exercised - (89,192) - (11,230) 0.46 --------------- ------------------------------------------- Balance at December 31, 1996 3,598,754 206,228 506,359 5,000 $3.47 =============== ===========================================
6. Stock Option and Purchase Plans (continued)
Options Outstanding Options Exercisable ------------------------------------------------ --------------------------------- Weighted Weighted Average Weighted Average Remaining Average Range of Number Exercise Contractual Number Exercise Exercise Prices Outstanding Price Life Exercisable Price - -------------------------- ------------------------------------------------ --------------------------------- $1.41 - $2.50 38,416 $1.94 5 36,749 $1.92 $2.51 - $3.00 282,154 $2.85 9 252,706 $2.84 $3.01 - $3.44 181,912 $3.25 7 153,002 $3.23 $3.75 64,037 $3.75 7 55,707 $3.75 $3.94 - $7.69 151,068 $5.21 5 151,068 $5.21 ----------------- ----------------- 717,587 $3.47 7 649,232 $3.51
Options Outstanding Options Exercisable --------------------------------------------------------- Weighted Weighted Range of Average Average Exercise Number Exercise Number Exercise Option Plan Price Outstanding Price Exercisable Price - ----------------------------------- ---------------- --------------------------------------------------------- 1983 Incentive Stock Option Plan $1.41 - $7.19 206,228 $4.31 206,228 $4.31 1993 Equity Compensation Plan $2.25 - $7.69 506,359 $3.12 438,004 $3.12 Non Employee Director Plan $4.63 5,000 $4.63 5,000 $4,63 --------------- --------------- 717,587 $3.47 649,232 $3.51
Nonqualified Stock Options On July 1, 1987, the Company granted nonqualified options to purchase 66,667 shares of common stock to an officer at $14.70 per share. Subsequently, 26,667 of the options were canceled and reissued under the Incentive Stock Option Plan and the remaining 40,000 options were canceled and reissued at $7.50 per share. In September 1988 the officer exercised options to purchase 13,334 shares of common stock. Pursuant to the terms of the option agreement, the Company provided a loan to the officer for the amount of the 6. Stock Option and Purchase Plans (continued) funds necessary to exercise the options. In May 1990, the remaining 26,666 options were canceled and reissued at $3.75 per share. In July 1996, the officer resigned from the Company. As part of the resignation agreement, the Company forgave the outstanding loan in return for 13,334 shares of common stock. On August 10, 1988, the Company granted nonqualified options to purchase 6,667 shares of common stock to an officer at $3.75 per share. At December 31, 1996, 6,667 options are exercisable. On January 14, 1993, the Company granted nonqualified options to purchase 7,760 shares of common stock to a director at $8.19 per share. At December 31, 1996, the 7,760 options are exercisable. The shares of common stock covered by these nonqualified options are restricted as to transfer under applicable securities laws. Qualified Employee Stock Purchase Plan The Company has a Qualified Employee Stock Purchase Plan (the "Purchase Plan") under which all employees meeting certain criteria may subscribe to and purchase shares of common stock. The number of shares of common stock authorized to be issued under the Purchase Plan is 500,000. The subscription price of the shares is 85% of the fair market value of the common stock on the day the executed subscription form is received by the Company. The purchase price for the shares is the lesser of the subscription price or 85% of the fair market value of the shares on the day the right to purchase is exercised. Payment for common stock is made through a payroll deduction plan. The Company applies Accounting Principles Board Opinion No. 25, "Accounting for Stock Issued to Employees", and related interpretations, in accounting for its stock-based compensation plans. Accordingly, no compensation expense has been recognized for its stock option awards, because the exercise price of all options equals the market price of the stock on the grant date. Had compensation expense for the Company's stock option awards been determined based upon 6. Stock Option and Purchase Plans (continued) their grant date fair value consistent with the methodology prescribed under Statement of Financial Accounting Standards No. 123, "Accounting for Stock-Based Compensation", the Company's net loss and loss per share would have been increased by $435,000 or $.01 per share and $162,000, or $.02 per share for 1996 and 1995, respectively. These amounts are not necessarily indicative of the amounts that will be reported in the future. The fair value of the options at the grant date was estimated using the Black-Scholes model with the following weighted average assumptions: 1996 1995 ------------------------------------ Expected life (years) 5 5 Interest rate 6.0% 6.0% Volatility 119.5% 119.5% Dividend yield 0% 0% 7. Leases The Company leases office and research facilities from a director under a month-to-month operating lease. Rental payments to the director were approximately $122,000, $121,000 and $119,000 for the years ended December 31, 1996, 1995 and 1994, respectively. The Company leases other offices and facilities and office equipment under certain operating leases which expire on various dates through April 2000. Under the terms of the facility leases, a pro rata share of operating expenses and real estate taxes are charged as additional rent. See also Note 8 regarding restructuring costs relative to certain facility leases. The Company subleases one of its facilities to another party whereby that party makes payments directly to the lessor. 7. Leases (continued) As of December 31, 1996, the Company is obligated for future minimum lease payments without regard for sublease payments under noncancelable leases as follows (in thousands): 1997 $1,246 1998 674 1999 372 2000 77 --------- $2,369 ========== Rent expense (including amounts for the facilities leased from the director) amounted to $638,000, $435,000 and $410,000 for the years ended December 31, 1996, 1995 and 1994, respectively. 8. Restructuring Costs During 1996 the Company recorded restructuring costs of $2,449,000 as a result of the consolidation of the laboratory operations of PDLA into the laboratory operations at Medtox, the sale of the former operations of Bioman, and the reduction of its work force at certain of its facilities. The following information presents the restructuring costs recorded in 1996. Severance costs $ 907,000 Lease obligations 967,000 Write off of assets 284,000 Other miscellaneous costs 291,000 ------------ $2,449,000 ============ At December 31, 1996 the Company has accrued $1,466,000 for the continued rental obligations and associated costs for the former PDLA laboratory facility in New Jersey and a former Medtox laboratory facility in Illinois. These facilities are currently idle. The Company has calculated the net present value of the remaining payments and charges utilizing a discount rate of 9%. In addition, the Company has accrued $337,000 at December 31, 1996 for severance costs. 9. Income Taxes Deferred income taxes reflect the tax effects of temporary differences between the carrying amounts of assets and liabilities for financial reporting purposes and the amounts used for income tax purposes. Significant components of the Company's deferred tax liabilities and assets are as follows:
December 31 1996 1995 ------------------------------- (In thousands) Deferred tax liabilities: Capital leased assets $ - $ 6 ---------------------------------- Total deferred tax liabilities - 6 Deferred tax assets: Excess fixed asset basis 315 153 Excess goodwill basis 2,154 - Net acquisition costs 241 241 Net operating loss carryforwards 11,254 11,271 Research and experimental credit carryforwards - 456 Uniform capitalization reserve - 22 Restructuring costs 672 157 Legal reserve 198 - Other 418 160 ------------------------------------ Total deferred tax assets 15,252 12,460 Valuation allowance for deferred assets (15,252) 12,454 ------------------------------------ Total deferred tax assets - 6 ------------------------------------ Net deferred tax assets (liabilities) $ - $ - ====================================
9. Income Taxes (continued) At December 31, 1996, the Company has operating loss carryforwards available to offset future taxable income for federal tax purposes of approximately $33,100,000 expiring in 1998 through 2011. The Company acquired approximately $2,473,000 in net operating loss carryforwards when it purchased PDLA. This amount is included in total net operating loss carryforwards described in the preceding paragraph. Future use of this carryforward will be limited based on the Separate Return Limitation Year ("SRLY") Rules found in Proposed Treasury Regulation 1.1502-21(c). These rules limit the use of a net operating loss carryforward into consolidated return years. The limitation, computed annually, limits the use of the SRLY net operating loss carryforward to the cumulative annual taxable income generated by the purchased company since its admittance into the consolidated group. The annual usage of the Company's net operating loss carryforwards has been limited by provisions of the Tax Reform Act of 1986 ("TRA"). Under TRA, if a company experiences a change in ownership of more than 50% (by value) of its outstanding stock over a three year period, the use of its pre-change in ownership net operating loss carryforwards will be limited each year until the loss is exhausted or the carryover period expires. Changes in ownership occurred at the time of the Company's 1987 public stock offering and in 1996 at the time the Company sold Series A preferred stock and acquired Medtox. The amount of pre-change in ownership net operating loss carryforwards of approximately $30,000,000 which can be utilized to offset future federal taxable income will be approximately $2,000,000 per year. TRA does not limit annual usage of post-change in ownership net operating loss carryforwards. 10. Benefit Plans The Company has defined contribution benefit plans that cover substantially all employees who meet certain age and length of service requirements. Contributions to the plans are at the discretion of the Board of Directors. The 401(k) expense for the years ended December 31, 1996, 1995 and 1994 was $80,000, $-0-, and $-0-, respectively. 11. Contingencies The Company was sued in Federal District Court for the Southern District of New York in five separate lawsuits commenced by holders of Editek Series A Convertible Preferred Stock. The lawsuits allege breach of contract with respect to conversion of the Preferred Stock in regards to the Company's inability to issue common stock upon the conversion of shares of preferred stock, and certain plaintiffs have also alleged misrepresentation and securities laws violations in connection with the sale of the Preferred Stock. In December 1996, the Company's shareholders approved an increase in the authorized common stock of the Company. Subsequently, four of the five lawsuits have been settled. The remaining lawsuit alleges breach of contract and fraud in connection with the Company's inability to convert preferred stock into common stock due to the previous unavailability of sufficient common shares. The common stock has subsequently been delivered, but plaintiffs continue to assert claims of money damages resulting from alleged delays in effecting the conversions. The Company intends to vigorously contest the matter. The Company is a defendant to claims of patent infringement asserted on August 20, 1996. It is alleged the Company infringes two patents allegedly owned by the plaintiff relating to forensically acceptable determinations of gestational fetal exposure to drugs and other chemical agents. The Company has answered the compliant denying any infringement and has counterclaimed for a declatory judgment that the patents are invalid, unenforceable, and not infringed. It also has counterclaimed for unfair competition under federal and state law, requesting money damages as well as injunctive relief. The Company intends to vigorously pursue its defense of the claims and to vigorously prosecute its counterclaims. The Company believes that the probable resolution of the above contingencies will not materially affect the financial position or results of operations of the Company. On January 31, 1997, the Company filed suit in Federal District Court in Minnesota against a majority shareholder and two outside directors of the Company alleging violation of Section 16b of the Securities Exchange Act of 1934 and seeking recovery of more than $500,000 in short-swing profits. No answer to the Company's complaint has yet been received from the defendants. 12. Restatement In March 1997, the Securities and Exchange Commission Staff (the "Staff") announced its position on accounting for preferred stock which is convertible into common stock at a discount from the market rate at the date of issuance. The Staff's position is that a preferred stock dividend should be recorded for the difference between the conversion price and the quoted market price of common stock at the date of issuance. To comply with this position, the Company restated its 1996 loss applicable to common stockholders to reflect a deemed dividend of $6,783,333 related to the January 1996 sales of the Series A Preferred Stock discussed in Note 5. The restatement resulted in an increase in the previously reported net loss per share applicable to common stockholders to $.59 from the previously reported amount of $.38. EX-24.1 2 EXHIBIT 24.1 EXHIBIT 24.1 Consent of Independent Auditors We consent to the incorporation by reference in Registration Statements No. 333-24371 on Form S-8 dated April 2, 1997, No. 333-18547 on Form S-3 dated February 14, 1997, No. 333-827 on Form S-3 dated May 15, 1996, No. 33-89646 on Form S-8 dated February 21, 1995, No. 33-91840 on Form S-3 dated July 21, 1995, No. 33-86744 on Form S-3 dated December 13, 1994, No. 33-78590 on Form S-3 dated June 20, 1994, No. 33-74078 on Form S-3 dated February 2, 1994, No. 33-71490 on Form S-8 dated November 11, 1993, No. 33-71596 on Form S-8 dated November 11, 1993, No. 33-49474 on Form S-8 dated July 10, 1992, No. 33-48566 on Form S-3 dated June 25, 1992, No. 33-15025 on Form S-8 dated June 29, 1987 and No. 33-10393 on Form S-8 dated December 16, 1986 of our report dated February 21, 1997, except for Note 12, as to which the date is July 18, 1997, with respect to the consolidated financial statements and schedule of EDITEK, Inc. included in the Annual Report (Form 10-K/A-2) for the year ended December 31, 1996. /s/ Ernst & Young LLP Minneapolis, Minnesota September 16, 1997 EX-27 3 EXHIBIT 27 (FDS)
5 1,000 YEAR DEC-31-1996 JAN-01-1996 DEC-31-1996 82 0 4,911 358 1,290 6,065 10,129 7,951 24,079 9,627 0 0 0 3,834 9,714 24,079 26,498 26,726 17,495 39,535 0 0 469 (12,809) (0) (12,809) 0 6,783 0 (19,592) (.59) 0
-----END PRIVACY-ENHANCED MESSAGE-----